Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kala BioKALA +4.70%18 5-Year Yield-on-Cost % is 0.00 as of Aug. 01, 2026. GuruFocus rates KALA with a GF Score™ of 18/100. The stock has 2 warning signs investors should review. Among 150 Biotechnology companies, Kala Bio ranks worse than 666666% on this metric.
Kala Bio's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Kala Bio's 5-Year Yield-on-Cost % or its related term are showing as below:
KALA's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.71 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Kala Bio (NAS:KALA) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Kala Bio 5-Year Yield-on-Cost % Related Terms
KALA vs GDTC, GTBP, INAB: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Kala Bio's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kala Bio 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kala Bio's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Kala Bio's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Kala Bio is calculated as
Kala Bio (KALA) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 01, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Kala Bio and its competitors. According to the industry distribution chart, Kala Bio ranks #999999 out of 150 companies in the Biotechnology industry.
Is Kala Bio's 5-Year Yield-on-Cost % too high?
Kala Bio's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Kala Bio ranks #999999 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kala Bio has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Kala Bio's 5-Year Yield-on-Cost % compare to GDTC and GTBP?
According to the Biotechnology industry distribution chart, Kala Bio ranks #999999 out of 150 companies for 5-Year Yield-on-Cost %. This places Kala Bio in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.71. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.71, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Kala Bio and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kala Bio's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kala Bio stock overvalued right now?
Kala Bio (KALA) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Kala Bio's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Kala Bio (KALA), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
18GF Score
Get the complete analysis for KALA
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KALA has been successfully added to your 
